oversold low end sale rang doabl
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
lower sales/ep po lower
mylan result under-perform our/con revenu forecast believ
key reason sharp stock sell-off perform
busi in-lin expect key us market europ
notabl laggard sale declin y/i constant currenc basi management
reiter financi target believ clearli becom show-m
stori complex specialti launch underwhelm expect region
sale guidanc includ north america high sd eu mid-sd report
basi appear challeng follow result follow result lower
sale limit chang north america row estim
lower europ number revis ep prior assum lower
sale slightli lower opex base chang lower ev/ebitda multipl
vs prior due sector de-rat lower po
takeaway eu pharma drag serial
approach encod drug combat counterfeit myl intern site ready-
to-go integr partner creat backlog compani believ
provid catch-up opportun futur quarter ex-seri management said
isol cc growth eu would flat vs y/i report sale
partnership management advisori firm separ on-going strateg review
management hire advisor help focu compani strategi profit product
channel mix recal activ prune product portfolio
transit toward complex specialty/biolog product quarterli
sale progress sale contribut full-year sale mid-pt
expect back-load year repres
model benefit larger share new market increment sales/market
effort new product contribut come carryov launch
us decent run-rat get annual goal
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global pharmaceut compani
develop manufactur market
pharmaceut product span three segment
gener over-the-count brand specialti
product north american biggest market
account approxim total
sale follow europ
remaind rest world becom
one largest specialti gener player
combin organ growth
number signific acquisit
rate buy abat concern around
us gener industry-level gener price
show sign stabil improv new
integr undemand valuat
share trade impli ev/ebitda
multipl versu peer group averag
price object po base multipl ebitda
rel gener peer believ share trade similar
multipl gener peer lower closest peer teva consensu
furthermor less visibl earn profil view compani
gener growth driver less durabl sourc growth teva key spec brand
believ dcf appropri valuat methodolog
littl visibl outlook beyond one two year multipl take
follow consider on-going launch g-advair gener advair relat
conting payment mid-single-digit growth eu row busi
risk po greater-than-expect competit pressur copaxon gener
failur monet new product launch opportun increas price pressur
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
